These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37574431)

  • 1. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study.
    Saibeni S; Bezzio C; Bossa F; Privitera AC; Marchi S; Roselli J; Mazzuoli S; Geccherle A; Soriano A; Principi MB; Viola A; Sarpi L; Cappello M; D'Incà R; Mastronardi M; Bodini G; Guerra M; Benedetti A; Romano M; Cicala M; Di Sabatino A; Scaldaferri F; De Rosa T; Giardino AM; Germano V; Orlando A; Armuzzi A
    Dig Liver Dis; 2024 Jan; 56(1):83-91. PubMed ID: 37574431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months.
    Teich N; Grümmer H; Jörgensen E; Liceni T; Holtkamp-Endemann F; Fischer T; Hohenberger S
    BMC Gastroenterol; 2021 Apr; 21(1):161. PubMed ID: 33845784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis).
    Probert CS; Sebastian S; Gaya DR; Hamlin PJ; Gillespie G; Rose A; Tate H; Wheeler C; Irving PM
    BMJ Open Gastroenterol; 2018; 5(1):e000212. PubMed ID: 30002864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of biological interventions for ulcerative colitis on health-related quality of life.
    LeBlanc K; Mosli MH; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece.
    Gatopoulou A; Christodoulou DK; Katsanos KH; Bakos D; Mouzas I; Tzouvala M; Theodoropoulou A; Paspatis G; Theocharis G; Thomopoulos K; Giouleme O; Kourikou A; Manolakopoulos S; Zampeli E; Michopoulos S; Karatzas P; Katsaros M; Moschovis D; Orfanoudaki E; Livieratos A; Petrikkou E; Mantzaris GJ
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e615-e624. PubMed ID: 34034278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results.
    Teich N; Grümmer H; Jörgensen E; Liceni T; Holtkamp-Endemann F; Fischer T; Hohenberger S
    World J Gastroenterol; 2020 Jun; 26(21):2852-2863. PubMed ID: 32550760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study.
    Berends SE; Strik AS; Jansen JM; de Boer NK; van Egmond PS; Brandse JF; Mathôt RA; D'Haens GR; Löwenberg M
    Scand J Gastroenterol; 2019 Jun; 54(6):700-706. PubMed ID: 31132014
    [No Abstract]   [Full Text] [Related]  

  • 9. Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study.
    Ferrante M; Schirbel A; Pierik MJ; Haas T; Flamant M; Khalifa A; Philip G; Cornillie F; Meehan AG; Govoni M
    Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):646-654. PubMed ID: 35412484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
    Dubinsky MC; Jairath V; Feagan BG; Naegeli AN; Tuttle J; Morris N; Shan M; Arora V; Lissoos T; Agada N; Hibi T; Sands BE
    BMJ Open Gastroenterol; 2023 Mar; 10(1):. PubMed ID: 37001911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
    Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
    World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in Chinese patients with mild and moderately active ulcerative colitis.
    Zheng K; Zhang S; Wang C; Zhao W; Shen H
    PLoS One; 2015; 10(4):e0124211. PubMed ID: 25915777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program.
    Dubinsky MC; Armuzzi A; Gecse KB; Ullman T; Bushmakin AG; DiBonaventura M; Cappelleri JC; Connelly SB; Woolcott JC; Salese L
    Dig Dis; 2023; 41(4):604-614. PubMed ID: 36603566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.
    Detrez I; Dreesen E; Van Stappen T; de Vries A; Brouwers E; Van Assche G; Vermeire S; Ferrante M; Gils A
    J Crohns Colitis; 2016 May; 10(5):575-81. PubMed ID: 26738756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
    Feagan BG; Sands BE; Sandborn WJ; Germinaro M; Vetter M; Shao J; Sheng S; Johanns J; Panés J;
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):307-320. PubMed ID: 36738762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.
    Reinisch W; Colombel JF; Gibson PR; Rutgeerts P; Sandborn WJ; Tarabar D; Huyck S; Khalifa A; Marano C; Philip G; Yao R; Zhang H; Cornillie F
    Inflamm Bowel Dis; 2019 Jan; 25(1):163-171. PubMed ID: 29982631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain.
    Targownik L; Dubinsky MC; Steinwurz F; Bushmakin AG; Cappelleri JC; Tai E; Gardiner S; Hur P; Panés J
    J Crohns Colitis; 2023 Apr; 17(4):513-523. PubMed ID: 36271912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study.
    Yu J; Park SJ; Kim HW; Lim YJ; Park J; Cha JM; Ye BD; Kim TO; Kim HS; Lee HS; Jung SY; Kim Y; Choi CH
    Gut Liver; 2022 Sep; 16(5):764-774. PubMed ID: 34959224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.